Abstract:

Objective To assess the efficacy and safety of anthracyclines in combination with taxanes for neo-adjuvant chemotherapy in patients with breast

cancer. Methods The data of 192 breast cancer patients treated by taxanes and anthracyclines neoadjuvant regimens was reviewed. The efficacy and safety of

taxanes and anthracyclines neoadjuvant regimens， as well as factors influencing pathological complete remission were analyzed. Results The efficacy of 192

patients could be evaluated. The effective rate was 84.9% （163/192），and the overall pathologic complete remission rate was 20.3%（39/192）. The complete

remission rates were 8.5%（10/118）in patients of HR（+）/HER-2（-）subtype， 42.8%（6/8）in patients of HR（-）/HER-2（+）subtype， 25.0%（5/20）in patents of HR（+）/HER-2（+） subtype， and 45.0%（18/40）in patients of HR-/HER-2-subtype. The logistic regression revealed that ER status affected the complete remission rate after neoadjuvant chemotherapy of the breast cancer. The main dose limiting toxicities was grade 3/4 neutropenia （94.7%）. Other non-hematologic toxicities included grade 2/3 vomitting （6.2%）， bone pain （14.1%）， febrile neutropenia （16.7%）， mucocitis （2.1%） and cardiotoxicity （5.7%） and etc. Conclusion Taxanes and anthracyclines chemotherapy regimens for the treament of patients with confirmed breast cancer show satisfied efficacy and safety， which can be regarded as an optimal neoadjuvant regimen for breast cancer.